Connect with us

Health

Endometrial cancer patients see new hope as FDA approves 'transforming' immunotherapy drug

Published

on

Endometrial cancer patients see new hope as FDA approves 'transforming' immunotherapy drug

Join Fox News for access to this content

Plus special access to select articles and other premium content with your account – free of charge.

By entering your email and pushing continue, you are agreeing to Fox News’ Terms of Use and Privacy Policy, which includes our Notice of Financial Incentive.

Please enter a valid email address.

Having trouble? Click here.

The U.S. Food and Drug Administration (FDA) has approved a new drug for certain adult patients with endometrial cancer.

Jemperli (dostarlimab-gxly) — made by British pharmaceutical company GSK — is intended for people with primary advanced or recurrent forms of the cancer, according to the FDA’s Aug. 1 announcement.

Advertisement

It is an immunotherapy-based drug, which means it leverages the body’s immune system to attack cancer cells.

SOME TAMPON PRODUCTS FOUND TO CONTAIN TOXIC METALS IN FIRST-TIME STUDY: ‘HARMFUL INGREDIENTS’

In clinical trials, Jemperli showed an improved progression-free survival and overall survival for all patients, according to Dr. Brian Slomovitz, director of gynecologic oncology and co-chair of the Cancer Research Committee at Mount Sinai Medical Center in Florida.

“This class of drugs has been used in the second-line setting,” Slomovitz said — meaning they were only used if a first-line (primary) treatment was not effective or had intolerable side effects.

The FDA has approved a new drug for certain adult patients with endometrial cancer. (iStock)

Advertisement

“Moving them to first-line [status] here will yield better outcomes.”

This is the third FDA approval this year for immunotherapy in endometrial cancer, the doctor noted.

THE 9 MOST COMMON QUESTIONS WOMEN OVER 40 ASK THEIR DOCTORS, ACCORDING TO A MENOPAUSE EXPERT

“This is great news for our patients,” Slomovitz told Fox News Digital.

“Endometrial cancer has become the leading cause of death over all other gynecologic cancers, including ovarian cancer.”

Advertisement

Jemperli (dostarlimab-gxly) — made by British pharmaceutical company GSK — is intended for people who have primary advanced or recurrent forms of the cancer. (iStock)

Before the immunotherapy options became available, the only treatment for endometrial cancer was chemotherapy alone, Slomovitz said. 

“These results are game-changing — it is unprecedented to have three approvals in such a short period of time.”

The most common side effects of all immunotherapy drugs are gastrointestinal, endocrine and dermatologic toxicities, the doctor noted.

“These results are game-changing — it is unprecedented to have three approvals in such a short period of time.”

Advertisement

“Patients should understand that adding immunotherapy to traditional chemotherapy has better results and the toxicity profile is manageable,” he added.

For doctors, Slomovitz emphasized the need to adjust quickly and make the newly approved drug a first-line treatment option for their patients.

GlaxoSmithKline (GSK) is the U.K.-based pharmaceutical company that makes Jemperli. (REUTERS/Dado Ruvic/Illustration/File Photo)

In June, the FDA approved Merck’s Keytruda (pembrolizumab) to be used in combination with chemotherapy for adult patients with primary advanced or recurrent endometrial cancer.

“The Merck trial (pembrolizumab) showed a significant improvement in progression-free survival for all patients,” Slomovitz said.

Advertisement

     

In that same month, AstraZeneca’s Imfinzi (durvalumab) was approved for patients with advanced or recurrent disease who have a certain biomarker.

The AstraZeneca trial also showed improved progression-free survival for all patients. 

All trials for the new cancer drugs were run through the GOG Foundation, which is the largest cooperative group for all gynecologic oncology research, Slomovitz noted. 

“The addition of immunotherapy to chemotherapy provided improvement in survival outcomes without a negative impact on quality of life,” an oncologist said. (iStock)

Advertisement

In the trials, the use of immunotherapy drugs in combination with chemotherapy reduced the risk of disease progression by approximately 70% in patients whose tumors had certain biomarkers.

In other patients without that biomarker, there was still a “clinically and statistically significant improvement in time to progression, which is meaningful for our patients and has now led to FDA approvals in both biomarker settings,” Kathleen N. Moore, M.D., co-director of the Stephenson Cancer Center at the University of Oklahoma Health Sciences Center, told Fox News Digital.

CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER

“These studies have transformed outcomes for patients with endometrial cancer and are poised to change the treatment landscape for the better into the future,” she added.

Shannon N. Westin, medical director of the Gynecologic Oncology Center at the University of Texas MD Anderson Cancer Center, said she is “thrilled” to have multiple new options for patients with advanced and recurrent endometrial cancer after years with no new therapies.

Advertisement

This is the third FDA approval this year for immunotherapy in endometrial cancer, the doctor noted. “This is great news for our patients,” an oncologist told Fox News Digital. (iStock)

“We no longer have to treat everyone in the same cookie-cutter fashion, and can instead employ precision medicine to improve survival for these survivors.”

For more Health articles, visit www.foxnews/health

“The addition of immunotherapy to chemotherapy provided improvement in survival outcomes without a negative impact on quality of life,” she went on. 

“This is the ideal scenario.”

Advertisement

Fox News Digital reached out to GSK for comment.

Health

‘Weight Loss Has Never Been About Calories’: How This Low-Insulin Diet Helped Lillie, 58, Drop 70 Lbs!

Published

on

‘Weight Loss Has Never Been About Calories’: How This Low-Insulin Diet Helped Lillie, 58, Drop 70 Lbs!


Advertisement


Low-Insulin Diet Helped Lillie, 58, Drop 70 Lbs, No Calorie Counting! | Woman’s World




















Advertisement











Advertisement




Use left and right arrow keys to navigate between menu items.


Use escape to exit the menu.

Advertisement

Continue Reading

Health

Weight-loss experts predict 5 major treatment changes likely to emerge in 2026

Published

on

Weight-loss experts predict 5 major treatment changes likely to emerge in 2026

NEWYou can now listen to Fox News articles!

Big moves are continuing in the weight loss landscape in the new year following breakthrough research of GLP-1 medications and other methods.

Weight-loss experts spoke with Fox News Digital about their predictions for the most major changes to come in 2026.

No. 1: Shift to whole-body treatment 

Dr. Peter Balazs, a hormone and weight loss specialist in New York and New Jersey, shared that the most important shift is likely to label GLP-1 drugs as “multi-system metabolic modulators” rather than “simple weight loss drugs.”

MORE AMERICANS MAY BE CLASSIFIED AS OBESE UNDER NEW DEFINITION, STUDY SUGGESTS

Advertisement

“The treatment goal is no longer just BMI reduction, but total cardiometabolic risk mitigation, with effects now documented across the liver, heart, kidneys and vasculature,” he said.

“We are seeing a significant reduction in major adverse cardiovascular events … and progression of renal disease,” he went on.

The focus of GLP-1 drugs will widen beyond weight loss and diabetes, according to experts’ predictions. (iStock)

Philip Rabito, M.D., a specialist in endocrinology, weight loss and wellness in New York City, also shared that “exciting” advancements lie ahead for weight-loss drugs, including GLP-1s and GIPs.

OLDER AMERICANS ARE QUITTING GLP-1 WEIGHT-LOSS DRUGS FOR 4 KEY REASONS

Advertisement

“These next‑generation agents, along with novel combinations that include glucagon and amylin agonists, are demonstrating even more impressive weight‑loss outcomes than currently available therapies, with the potential for better tolerability and sustained results,” he told Fox News Digital.

“There is also tremendous optimism around new federal agreements with manufacturers that aim to make these medications more widely accessible and affordable for the broad population of patients who need them most.”

No. 2: More convenient dosing

The typical prescription for a GLP-1 medication is a weekly injection, but delivery and dosing may be changing to more convenient methods in 2026, according to Balazs.

OPRAH JOINS WAVE OF CELEBRITIES WHO REVEALED DRAMATIC WEIGHT LOSS IN 2025

A daily 25 mg pill version of Novo Nordisk’s Wegovy, a semaglutide designed to treat obesity, is now approved and available for chronic weight management, offering a non-injectable option for some patients.

Advertisement

A once-weekly oral GLP-1 is currently in phase 2 trials, as well as an implant that aims for three to six months of drug delivery, Balazs noted.

Incisionless weight-loss procedures will rise as a lower-risk option, according to experts. (iStock)

No. 3: Less invasive surgery

In addition to decreased risk during surgery for GLP-1 users, Balazs also predicted that metabolic surgery without incision will rise as a better option.

“Incisionless endoscopic procedures — like endoscopic sleeve gastroplasty (non-surgical weight-loss procedure that makes the stomach smaller from the inside) and duodenal mucosal resurfacing (non-surgical procedure that resets part of the small intestine to help the body better handle blood sugar) — [may become] more durable and widely available,” he said. 

TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ

Advertisement

“These offer significant metabolic benefits with shorter recovery and lower risk than traditional surgery.”

Rabito agreed that “rapid progress” in minimally invasive weight‑loss procedures is “opening powerful new options for patients who are hesitant to pursue traditional bariatric surgery.”

Bariatric surgery remains the most effective weight loss method, one specialist says. (iStock)

This avenue offers “meaningful and durable weight reduction with less risk, shorter recovery times and no external incisions,” the expert added.

Dr. Muhammad Ghanem, bariatric surgeon at the Orlando Health Weight Loss & Bariatric Surgery Institute, reiterated that surgery remains “the most successful modality for the treatment of obesity … with the highest weight loss and most durable outcomes as of yet.”

Advertisement

No. 4: Younger GLP-1 users

As Novo Nordisk’s Wegovy has been indicated for adolescents over 12 years old as an obesity treatment, Balazs commented that pediatric use of weight-loss drugs is “now a clinical reality.”

He predicted that other alternatives are likely to be approved in 2026 for younger users.

No. 5: High-tech, personalized access

Amid the growth of artificial intelligence, Balazs predicted an expansion in the clinical implementation of AI-driven weight-loss methods.

CLICK HERE TO DOWNLOAD THE FOX NEWS APP

This could include categorizing obesity into sub-types like “hungry brain,” “emotional hunger” and “slow burn” to personalize how therapy is prescribed while moving away from “trial and error,” he said.

Advertisement

Ghanem agreed that there will likely be a “big focus” on individualized testing for causes of obesity in 2026, as it’s a disease that can have “different causes in different people,” thus requiring different treatments.

AI and other digital opportunities will drive more access for weight-loss patients, experts say. (iStock)

The doctor anticipates that more patients will seek combinations of comprehensive treatments and programs.

“Patients are more aware that now we have a few weapons in our arsenal to combat obesity, and [they] are seeking a multidisciplinary and holistic approach,” Ghanem said.

CLICK HERE FOR MORE HEALTH STORIES

Advertisement

Treatment options will also turn digital with the rise of prescription digital therapeutics (PDTs) for weight loss, Balazs predicted.

“These are software applications delivering cognitive behavioral therapy, personalized nutrition and metabolic coaching through algorithms, often integrated with continuous glucose monitors, and reimbursed as medical treatments,” he said.

CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER

Ghanem added that body composition analyzers, like DEXA scans, will likely be more widely used as awareness grows about the limitations of BMI and weight in assessing obesity.

Advertisement
Continue Reading

Health

Brain Health Challenge: Doctor Appointments for Your Mind and Body

Published

on

Brain Health Challenge: Doctor Appointments for Your Mind and Body

Congratulations, you’ve reached the final day of the Brain Health Challenge! Today, we’re asking you to do a few things that might feel a bit out of left field — like getting your blood pressure checked.

No, it isn’t as fun as playing Pips, but experts say it’s one of the most important things you can do for your brain. That’s because heart health and brain health are intrinsically linked.

Advertisement

High blood pressure, in particular, can damage brain cells, and it’s a significant risk factor for stroke and dementia. When blood pressure is too high, it places stress on the walls of arteries in the brain. Over time, that added stress can cause the blood vessel walls to thicken, obstructing blood flow. In other cases, the increased pressure causes the artery walls to thin and leak blood into the brain.

These changes to the blood vessels can sometimes cause a large stroke to occur. More commonly, the damage leads to micro-strokes and micro-hemorrhages, which cause fewer immediate problems and often go unnoticed. But if someone has hypertension for years or decades, these injuries can build up, and the person may start to experience cognitive impairment.

Advertisement

High blood pressure “is known as a silent killer for lots of reasons,” said Dr. Shyam Prabhakaran, the chair of neurology at the University of Chicago. “It doesn’t cause you any symptoms until it does.”

Because the damage accumulates over many years, experts say that managing blood pressure in midlife matters most for brain health. Hypertension can be addressed with medication or lifestyle changes, as directed by your doctor. But the first thing you need to do is know your numbers. If your blood pressure comes back higher than 120/80, it’s important to take it seriously, Dr. Prabhakaran said.

While you’re at it, there are a few other aspects of your physical health that you should check on.

Advertisement

Your eyes and ears are two of them. Hearing and vision loss have both been shown to increase the risk of dementia. Experts think that with less sensory information coming in to stimulate the brain, the regions that process hearing and vision can start to atrophy. What’s more, people with sensory loss often withdraw or are left out of social interactions, further depriving them of cognitive stimulation.

Oral health can also affect your brain health. Research has found a connection between regular flossing and reduced odds of having a stroke. That may be because good oral health can help to reduce inflammation in the body. The bacteria that cause gum disease have also been tied to an increased risk of Alzheimer’s.

Advertisement

And have you gotten your shingles vaccine? There is mounting evidence that it’s a powerful weapon for protecting against dementia. One study found that it lowered people’s odds of developing the condition by as much as 20 percent.

To wrap up this challenge, we want you to schedule a few medical appointments that benefit your brain, as well as your body.

After five days of feeding, exercising and challenging your brain, you are well on your way to better cognitive health. Thanks for joining me this week, and keep up the good habits!

Advertisement

Continue Reading

Trending